One Insurance Contract Clause That Defines a Heart Attack as Tissue Damage You Cannot Prove
You buy a critical-illness policy expecting a lump sum if you survive a heart attack. The marketing material shows a family relieved, a check in hand. What the brochure does not show is the definition buried in the contract appendix: a heart attack, for insurance purposes, is not chest pain, not a stent, not even a diagnosis from your cardiologist. It is irreversible tissue necrosis, confirmed by a specific rise in cardiac enzymes or ECG changes that meet a threshold you may never reach. That single clause turns a claim into a fight.
The Clause That Insurers Wrote
Open a typical critical-illness policy and you will find the heart attack definition tucked inside a section labelled “Covered Conditions.” It reads something like this: “Myocardial infarction means the death of a portion of the heart muscle as a result of inadequate blood supply, with evidence of characteristic enzyme elevation and typical ECG changes.” The word “death” is the trap. Insurers require proof that tissue has already died, not that it was at risk.
The definition demands two kinds of evidence: a rise in cardiac biomarkers such as troponin or CK-MB above a specified threshold, and ECG changes consistent with an acute infarct. In practice, many heart attacks—especially those treated early with angioplasty or medication—do not produce enzyme levels that high. The muscle is saved, the patient lives, but the insurance definition is not met.
Consumer advocates call it a claims trap. A 2023 report from the Consumer Federation of America found that roughly one in five heart-attack claims on individually sold critical-illness policies were denied, with the narrow definition cited as the primary reason in more than half of those denials. Insurers defend the language as necessary to distinguish a true heart attack from angina or other cardiac events that do not cause permanent damage.
The fine print is not in the policy summary. It is in the appendix, often printed in a font two points smaller than the main text. Agents rarely walk clients through it. The result is a product that pays out less often than buyers expect.
Why Tissue Necrosis Became the Standard
The narrow definition did not emerge from medical consensus. It was lobbied into existence. In the early 1990s, as critical-illness insurance gained popularity in the United States, insurers pushed for a uniform model that would limit payouts. The National Association of Insurance Commissioners (NAIC) adopted a model act in 1996 that codified the tissue-necrosis standard. Roughly 40 states followed, either by adopting the model directly or by approving policy forms that mirrored it.
Insurers argued that a broader definition would turn the product into a cash-for-diagnosis program. They warned that every case of unstable angina or minor enzyme leak would trigger a claim, forcing premiums higher. The medical community pushed back, noting that modern cardiology defines heart attack by a combination of symptoms, biomarkers, and imaging—not solely by necrosis. But the insurance lobby had the ear of regulators.
Policyholders rarely read the contract appendix. A 2019 study by the Journal of Insurance Regulation found that fewer than 10% of critical-illness buyers recalled seeing the definition of a covered condition before purchase. Most relied on the agent’s description or the brochure’s plain language. The appendix is dense, full of cross-references and exclusionary clauses that even lawyers find tedious.
The result is predictable: a claim is submitted, the insurer requests medical records, and a claims examiner—often a nurse or a physician’s assistant—reviews whether the enzyme levels hit the magic number. If they did not, the claim is denied. The patient, already recovering from a cardiac event, must now fight an insurance company while paying hospital bills.
The Tax Twist No One Talks About
Denied claims are bad enough, but the tax treatment of critical-illness payouts adds another layer of pain. Under current IRS rules, a critical-illness policy that meets the definition of a “qualified long-term care contract” or is structured as an accelerated death benefit may receive favorable tax treatment. But many standalone critical-illness policies do not qualify. If the policy fails the definition—meaning the claim is denied—the IRS may treat the payout as a non-qualified distribution, subject to ordinary income tax.
Freelancers and self-employed buyers face the worst of it. They purchase policies with after-tax dollars, expecting a tax-free benefit. If the claim is denied, they lose both the benefit and the tax deferral they assumed. Some policies include a return-of-premium feature, but that is often taxed as income if paid out. The tax code has not caught up to the product design.
Expats face double taxation without proper structure. A U.S. citizen living abroad who buys a critical-illness policy from a foreign insurer may find the payout subject to U.S. income tax and local tax, with no treaty relief. The narrow definition becomes a cross-border trap: the foreign insurer may have its own definition, but the IRS applies U.S. standards to determine whether the payout is a return of capital or income. Without careful planning, a denied claim can trigger a tax bill larger than the premium saved.
A 2025 white paper by the American Institute of CPAs (AICPA) on insurance taxation noted that policyholders should verify whether their critical-illness policy qualifies under IRC Section 7702B for long-term care or as a life insurance rider. The AICPA found that fewer than 15% of standalone policies met the tax-favored criteria, leaving most buyers exposed to ordinary income tax on payouts. The institute recommended that buyers request a tax opinion letter from the insurer before purchase—a step almost no one takes.
Follow the Money: Who Profits
When a claim is denied, the insurer keeps the premium and pays nothing. That is the most direct profit center. According to the NAIC’s 2024 market report, critical-illness insurers collected roughly $3.2 billion in premiums and paid out $1.1 billion in claims, a loss ratio of about 34%. Health insurance loss ratios typically run 80% or higher. The difference is profit, commissions, and administrative costs.
Reinsurers price their coverage based on the narrow triggers. They assume that only a fraction of heart attacks will meet the definition, and they set their rates accordingly. If a primary insurer tried to broaden the definition, the reinsurance premium would rise, making the product less competitive. The entire chain—agent, carrier, reinsurer—has aligned incentives to keep the definition tight.
Brokers earn commissions on replacement policies. When a claim is denied, the policyholder may be told that the policy was “not right for them” and sold a new one with similar language. The broker earns a new commission, the insurer keeps the old premium, and the policyholder starts a new contestability period. A 2022 investigation by the New York Times found that some agents were explicitly trained to sell critical-illness policies to older clients, knowing the claim rate would be low.
State regulators collect fees on policy filings but rarely track claim-denial rates by condition. The NAIC’s complaint database lumps all critical-illness complaints together. Without condition-specific data, regulators have no easy way to spot a pattern of heart-attack denials. Insurers argue that the low complaint volume proves consumer satisfaction; critics say it proves that policyholders do not know they were denied for a definitional technicality.
Real-World Case: The Troponin Gap
Consider a 58-year-old teacher in Ohio who experienced chest pain while mowing his lawn. He drove himself to the emergency room, where doctors found a partially blocked artery. They performed angioplasty and placed a stent within two hours of his arrival. His peak troponin level was 1.5 ng/mL, roughly three times the upper limit of normal. His cardiologist diagnosed a non-ST-elevation myocardial infarction (NSTEMI). He recovered fully and returned to work after six weeks.
When he filed a claim on his critical-illness policy, the insurer requested his medical records. The policy required troponin elevation “greater than 5 times the upper limit of normal” along with ECG evidence of a new Q wave. His troponin was only three times normal, and his ECG showed no Q waves—the early treatment had prevented permanent damage. The claim was denied. The teacher appealed, providing a letter from his cardiologist confirming the diagnosis. The insurer upheld the denial, citing the policy language. He paid $4,200 in premiums over five years and received nothing.
Cases like his are not rare. A 2024 analysis by the advocacy group Fair Insurance Claims reviewed 200 denied heart-attack claims from five major insurers and found that 72% were denied solely because the enzyme levels did not meet the policy threshold, even though the treating physician diagnosed a heart attack. In 18% of those cases, the patient had undergone angioplasty or bypass surgery—procedures that typically prevent the very necrosis the policy requires.
How to Read Your Policy Before You Need It
Start with the definition section, not the brochure. Look for the words “myocardial infarction” and read the entire paragraph. Note the specific enzyme thresholds: troponin I or T, CK-MB, and the multiples of the upper limit of normal that the policy requires. Some policies say “greater than 2 times the upper limit of normal,” others “greater than 5 times.” The higher the multiple, the harder to meet.
Compare the policy language with the American Heart Association’s Fourth Universal Definition of Myocardial Infarction, published in 2018. The AHA recognizes a heart attack with a rise and fall of troponin above the 99th percentile of a normal reference population, along with symptoms or ECG changes. Many insurance policies require a level well above that, sometimes combined with evidence of new wall motion abnormality on an echocardiogram. The gap is clinical.
Consider riders that broaden the trigger. Some insurers offer a “heart attack and stroke” rider that uses a looser definition, often based on diagnosis by a cardiologist. The rider costs more, but it may pay out on events that the base policy would deny. Ask the agent for the paid-claim ratio on heart attacks for the specific policy you are considering. If the agent cannot provide it, that is a red flag.
Where Reform Is Stuck
The NAIC model act that codified the narrow definition has not been updated since 2000. Efforts to revise it have stalled. The insurance industry argues that any change would disrupt pricing and lead to adverse selection. Consumer groups counter that the model act was written before modern troponin assays and interventional cardiology made early treatment possible. The medical definition has evolved; the insurance definition has not.
Some states have attempted piecemeal reform. California requires insurers to disclose claim denial rates by condition, but the data is self-reported and not independently audited. New York’s Department of Financial Services issued a guidance letter in 2022 urging insurers to use the AHA definition, but compliance is voluntary. No state has mandated a specific definition.
The UK’s Financial Conduct Authority has been more active, requiring insurers to publish claims data by condition since 2018. That transparency has led some UK insurers to voluntarily broaden their definitions. But the U.S. market, with its state-by-state regulation and powerful industry lobby, has not followed. The NAIC’s next scheduled review of the critical-illness model act is 2028, barring an earlier push.
Your Next Move as a Buyer
Before you sign, request a sample claim form from the insurer. Look at the medical documentation they require. If the form asks for troponin levels and ECG interpretations, you know the definition will be strictly applied. Ask the agent for the paid-claim ratio on heart attacks for the specific policy you are considering. If the agent cannot provide it, that is a red flag.
Document any chest pain visit immediately. Even if you are not sure it is a heart attack, get the troponin test and keep the results. If you later need to file a claim, the insurer will request records from that visit. A single elevated troponin, even if it falls short of the policy threshold, can be used to argue that the event was cardiac. The burden of proof is on you.
If you already own a policy, read the definition now, not after an event. If the definition is narrow, consider supplementing with a hospital indemnity policy that pays a fixed amount per day of hospitalization, regardless of diagnosis. That product has no definitional trap and can cover the gap. No single policy covers everything. The trick is knowing what your policy actually covers before you need it.
The next time an agent tells you that a critical-illness policy pays a lump sum for a heart attack, ask for the definition in writing. Read it before you sign. The difference between a check and a denial is often just a few lines of text you never saw.
This article is for informational purposes only and does not constitute legal, tax, or insurance advice. Consult a qualified professional before making financial decisions.
